An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment.
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Lorcaserin (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Arena Pharmaceuticals
- 29 Mar 2017 Results assessing pharmacokinetics and tolerability of Lorcaserin in different populations in three studies (NCT00828581, NCT00828438, and NCT00828932) published in the Clinical Therapeutics
- 30 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jul 2009 Actual initiation date changed from Sep 2008 to Aug 2008 as reported by ClinicalTrials.gov.